Tag Archives: Eisai Europe Limited

Life Extending Metastatic Breast Cancer Treatment Halaven(R) (Eribulin) Launches in the United Arab Emirates

HATFIELD, England, April 22, 2015 / PRNewswire — Halaven(R) (eribulin) launches today in the United Arab Emirates (UAE) for the treatm…

Life-extending Advanced Breast Cancer Treatment Halaven(R) (Eribulin Mesylate) Launched in Kingdom of Saudi Arabia

HATFIELD, England, February 26, 2015 / PRNewswire –

– For EMEA media only: not for Swiss/U.S. Journalists

Innovative breast can…

Eisai Announces Partnership With Newbridge to Market Breast Cancer Treatment Halaven(R) (Eribulin) Across the Middle East

HATFIELD, England, November 18, 2013/PRNewswire-FirstCall –

Eisai announces today that Halaven(R) (eribulin) will be marketed in s…

Eisai Announces Availability of HalavenĀ® (eribulin) in Kuwait

HATFIELD, England, July 29, 2013 / PRNewswire –Partnership deal secured with Yiaco for Kuwait distribution

Eisai EMEA (Europe, the Mi